Nivolumab is currently being tested in multiple clinical trials, including for MSS CRC in combination with Encorafenib and Binietinib (NCT04044430), for MSS CRC in combination with the PI3Kinase inhibitor Copanlisib (NCT03711058), and in refractory metastatic MSS CRC, combined with the Epidermal Growth Factor Receptor (EGFR) competitive inhibitor Panitumumab and Ipilimumab (NCT03442569). Here, EGFR is linked to Marinesco-Sjogren syndrome.